Randomized phase <scp>II</scp> study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (<scp>STARGATE</scp>)Min‐Hee Ryu(Ulsan College), Yoon‐Koo Kang(Ulsan College)Cancer MedicineDecember 14, 202210.1002/cam4.5536Cited by 20SaveCiteExport RISWatch citationsRelated PapersTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial|The Lancet|2010|7.3kTremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma|NEJM Evidence|2022|1.4kEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial|The Lancet|2012|1.4kPembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial|The Lancet|2018|1.3kCapecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial|The Lancet Oncology|2013|838